Pharmacodynamics II, lect 3 Flashcards

1
Q

when spare receptors exist, the concentration-response curve (EC50) is shifted to the right or left?

A

Left; smaller dose concentrations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the relationship between EC50 and Kd when there are spare receptors

A

EC50 is lower than Kd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

identify 1 and 2

A
  1. agonist alone
  2. agonist + allosteric activator
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

identify 3 and 4

A
  1. agonist + competitive antagonist
  2. agonist + non-competitive antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what effect does a non-competitive antagonist have on an agonist

A

reduces the magnitude of the maximal response that can be attained by any amount of agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what effect does a competitive antagonist have on a agonist

A

affect the amount of agonist necessary to achieve a maximal response (does not affect the magnitude of the maximal response)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

competitive antagonist bind to the same receptor as agonist. What effect does this have on the agonist’s Kd? Does the curve shift to the right or left?

A
  • competitive antagonist decreases affinity (increases Kd) of an agonist for its receptor
  • curves of agonist shift to the right
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

As the concentration of antagonist increases, what happens to the potency of agonist

A
  • potency of agonist decreases (increases EC50)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

non-competitive antagonist act either allosterically or covalently. Describe both

A
  • allosteric: inhibit agonist binding at active site by binding to a secondary site on the receptor
  • covalent: irreversibly bind to the same site as agonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What effect does adding non-competitive antagonist have on the affinity (Kd) and potency (EC50) of agonist?

A

affinity (Kd) and potency (EC50) do not change

* E max decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is functional (physiological) antagonism

A
  • counteracts effects of agonist
  • generally not as specific or as easy to control
  • ex: reversing a fall in BP produced by histamine with epinephrine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is chemical antagonism

A
  • directly interacts with agonist and inactivates it
  • ex: inactivation heparin with protamine sulfate; neutralizing stomach acid with antacids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

partial agonist have what level of efficacy (alpha) compared to full agonist

A
  • lower efficacy
  • cannot produce the same maximal response as full agonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is Bmax

A

the maximum amount of drug that can bind speficially to the receptors; used to measure density of receptor site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

efficacy

A

describes the way that agonists vary in the response they produce when they occupy the same number of receptors. High efficacy agonists produce maximal response while occupying a relatively low proportion of total receptor population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

dose response curve for a partial agonist will have what Emax and Bmax compared to agonist

A
  • LOWER Bmax and Emax
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

if you have a single concentration of full agonist and increasingly add concentrations of a partial agonist,

  1. what happens to the response cause by the full agonist?
  2. What happens to the response caused by partial agonist?
  3. What happens to the total response?
A
  1. response caused by full agonist decreases
  2. response caused by partial agonist increases
  3. total response gradually decreases
18
Q

when partial agonist is added to a full agonist, why does the response caused by full agonist decrease ? Why does the total response gradually decrease?

A
  • partial agonist can act as competitive antagonist
  • bind to receptor, displacing the agonist and the overall effect is lower
19
Q

what is the primary function of intracellular receptors

A
  • modifies gene transcription and protein synthesis in the nucleus
  • effect in not immediate
  • effects are long lasting
20
Q

what type of ligans are able to stimulate intracellular receptors

A

lipid soluble ligands (hormones; steroid) : cross plasma membrane

21
Q

receptor tyrosine receptors are what type of receptors? How do they activate substrates when a ligand binds to them?

A
  • transmembrane proteins
  • ligand binding to receptor causes 2 receptors to dimerize and activate the kinase causing phosphorylation of the receptor and several down-stream substrates
22
Q

What is the mechanism of Imatinib (Gleevec)

A

anti-cancer agent: signal transduction inhibitor (STI)

23
Q

In cytokine receptors, where is the kinase activity?

A

in a seperate protein JAKs

24
Q

how do cytokine receptors work

A
  1. ligand binding causes receptors to dimerize
  2. JAKs phosphorylate tyrosine residues on recptor and activate STATs via phosphorylation
  3. STATs dissociate from receptor and regulate gene expression
25
Q

ions channels come into 2 forms: name them

A
  • ligand:ex: acetylcholine binds to nicotinic receptors which open Na+ channels and excites the cell
  • Voltage: ex: local anesthetics and anticonvulsants
26
Q

What is the effect of GABA on GABA receptors

A
  • the binding of GABA to GABA receptors open Cl- channels
  • hyperpolarizes (inhibits) the cell
27
Q

benzodiazepines, barbituates, and ethanol all act on what receptor to increase Cl- flow in the cell

A

GABA

28
Q

G protein coupled receptors come as Gs and Gi: what are the action of these

A
  • Gs: stimulatory; activate cAMP
  • Gi: inhibitory; inhibit cAMP
29
Q

List the steps associated with activation of G-protein receptor

A
  1. GTP binds and GDP is releases
  2. alpha unit of G-protein binds to adenylate cyclase to generate intracellular signal
  3. the signal is terminated by hydrolysis of GTP
30
Q

B1 and B2 are stimulate Gs or Gi

A

stimulate Gs and activate cAMP

31
Q

alpha2 stimulate Gs or Gi

A

stimulate Gi and inhibit cAMP

32
Q

what affect does G-protein receptor kinases (GRK) have on G-protein couples receptors

A
  • increases binding of B-arrestin and decreases the ability of the receptor to interact with G-protein
  • reduces response and “desensitizes” the receptor
33
Q

binding of B-arrestin has what effect on G-protein coupled receptors

A

increases endocytosis of the receptor

34
Q

In receptor-effector coupling, what is the function of coupling

A

the transduction process that links the drug-induced change in receptor conformation to the biological effect

35
Q

In receptor-effector coupling, what are the effectors

A

the mechanisms coupled to the receptor (Adenylate cyclase; phospholipase C (PLC), etc)

36
Q

in receptor-effector coupling, the biological effect is either what?

A
  • linear: (signal is 1-1)
  • amplified: biological response is greater than the degree of receptor occupancy
37
Q

adenylate cyclase has what effect on cAMP production

A
  • Gs proteins activate AC which results in the conversion of ATP to cAMP
38
Q

What are the major intracellular targets for cAMP? What function does cAMP have on the targets?

A
  • protein kinases (PKA; PKC)
  • kinases are composed of 2 regulatory (R) and 2 catalytic (C) subunits; binding of cAMP releases C unites that phosphorylate substrates
39
Q

Gq proteins activate what?

A

PLC

40
Q

After Gq activates PLC; what is the action of PLC

A

PLC hydolyzes PIP2 to form IP3 and DAG

41
Q

what is the function of IP3 and DAG

A
  • IP3 diffuses through the cytoplasm and releases Ca2+ from intracellular stores
  • DAG activates protein kinase C (PKC)
42
Q

how does nitric oxide elicit relaxation of vascular smooth muscle

A
  1. NO is a diffusable ligand that activates guanyl cyclase
  2. activated guanyl cyclase converts GTP to cGMP
  3. cGMP activates protein kinase G (PKG)
  4. PKG -> vasodilation